Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy
Company Announcements

Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy

Opthea Limited Sponsored ADR (OPT) has released an update.

Opthea Limited is set to make a significant impact at the upcoming 24th EURETINA Congress with presentations and a symposium on sozinibercept, a novel treatment for wet AMD that shows promise in outperforming current therapies. The company has completed patient enrollment for Phase 3 trials of sozinibercept and anticipates releasing topline data in early and mid-2025. These developments could position sozinibercept as the first new therapy in two decades to improve visual outcomes for wet AMD patients.

For further insights into OPT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskOpthea Limited Strengthens Leadership and Advances AMD Treatment
TheFlyOpthea executive director Megan Baldwin to retire from board
TipRanks Auto-Generated NewsdeskOpthea Advances Retinal Disease Treatments
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App